article thumbnail

Lilly blames slower-than-expected growth for 2024 sales miss

Bio Pharma Dive

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ramp-up in sales this year.

Sales 307
article thumbnail

In strengthening Spravato sales, a positive sign for psychedelic drugs

Bio Pharma Dive

Jefferies analyst Andrew Tsai views growing sales for J&J’s depression treatment as evidence that psychedelics like it can be commercially viable.

Sales 306
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Abeona secures cash runway with $155m priority review voucher sale

Pharmaceutical Technology

Abeonas deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

Sales 130
article thumbnail

Lilly shares fall as obesity drug sales miss forecasts

Bio Pharma Dive

Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter amid inventory decreases in the U.S.

Sales 291
article thumbnail

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Are you currently in sales, or involved in a business that depends on strong sales results? What about the extremely competitive world of medical device sales? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC., Toastmasters Champion.

article thumbnail

Novo boosts sales outlook on strong demand for obesity drug

Bio Pharma Dive

The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs.

Sales 328
article thumbnail

Pharma earnings outline drug law’s looming impact on sales, development

Bio Pharma Dive

While many companies are still unsure of the Inflation Reduction Act's effects, some have begun to warn investors about the likelihood of lower sales and reduced profitability.

Sales 322